ReviewBritish journal of cancer2009
A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas.
Review in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- Article
- Innate immunity in tumour immunoediting and immunosurveillance.The EMBO journal · 2026Review
- Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39.The Journal of experimental medicine · 2025Article
- FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma.Molecular cancer therapeutics · 2022Article
- Novel Mouse Models for Cancer Immunology.Annual review of cancer biology · 2022Article
- Article
- Resistance to chemical carcinogenesis induction via a dampened inflammatory response in naked mole-rats.Communications biology · 2022Article
- Article
- Type 1 Innate Lymphoid Cells Limit the Antitumoral Immune Response.Frontiers in immunology · 2021Article
- Article
- Loss of HIF-1α in macrophages attenuates AhR/ARNT-mediated tumorigenesis in a PAH-driven tumor model.Oncotarget · 2016Article
- Article
- Interleukin-27 signaling promotes immunity against endogenously arising murine tumors.PloS one · 2013Article
- Suppression, subversion and escape: the role of regulatory T cells in cancer progression.Clinical and experimental immunology · 2013Review
- Article
- [Prostate carcinoma: vaccination as a new option for treatment].Der Urologe. Ausg. A · 2012Review
- Defining the critical hurdles in cancer immunotherapy.Journal of translational medicine · 2011Article
- Dual biological effects of the cytokines interleukin-10 and interferon-γ.Cancer immunology, immunotherapy : CII · 2011Article
- The aging immune system and its relationship with cancer.Aging health · 2011Article
- The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory.BioEssays : news and reviews in molecular, cellular and developmental biology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The cancer immunoediting hypothesis has gained significant footing over the past decade as a result of work performed using sarcomas induced by 3-methylcholanthrene (3-MCA) in mice. Despite the progress made by several groups in establishing evidence for the three phases of immunoediting (elimination, equilibrium and escape), there continues to be active controversy on the nature of interaction between spontaneously formed tumour cells and the immune system during the early phases of tumourigenesis. At the root of this controversy is conflicting and unresolved evidence spanning back to the 1970s regarding the incidence and frequency of 3-MCA-induced sarcomas in immunocompetent mice as compared to immunodeficient mice. In this mini review we provide a critical analysis of both sides of this controversy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.